A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles